Search results

This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

Result type

Clinical guideline

Last updated

20 October 2017

Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

Result type

Technology appraisal guidance

Published

22 February 2006

Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

Result type

Technology appraisal guidance

Published

27 August 2008

Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

Result type

Technology appraisal guidance

Published

27 August 2008

Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

Result type

Technology appraisal guidance

Published

22 July 2009

Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

Result type

Technology appraisal guidance

Published

5 January 2022